Hutchison Medipharma hopes to break through with Volitinib for papillary renal cell carcinoma
SHANGHAI – Hutchison Medipharma Ltd. (HMP) is set to turn a corner announcing strong early results for not one, but three of its oncology drugs at ASCO 2014 this weekend in Chicago. Arguably the most exciting is the phase I data for Volitinib, a c-Met inhibitor that has shown strong results on patients with papillary renal cell carcinoma (PRCC), a rare form of cancer with no existing treatment.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter